The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2

Weeks 6-12: noticeable anti-aging effects This is where GHK-Cu shines: Clear skin texture improvement Visible firmness increase Fine lines reduced 20-40% Wrinkles softened Overall "younger" appearance Others start commenting Specific improvements by area: Face: Nasolabial folds (smile lines) softened Crow's feet reduced Forehead lines less pronounced Under-eye area firmer Jawline more defined Neck: Horizontal neck lines softer Crepey texture improved Firmness increased Less sagging Hands: Skin thickness increased Veins less prominent Age spots may lighten Texture smoother Expected improvements by week 12: Individual variation: Age: Younger skin responds faster Starting condition: More damage = more to improve Dose: Higher consistent doses = faster results Combination: Topical + injectable better Lifestyle: Sleep, diet, sun protection affect results Use SeekPeptides to track your GHK-Cu results timeline with photo comparison tools and progress metrics
Clin Chim Acta 2020;503:90-98
If youre looking for overall body recomposition, CJC1295 generally has a broader effect than AOD9604, especially when stacked with other GH secretagogues
(All of which, of course, also apply to Setria Glutathione)